Baker Bros. Advisors LP Otonomy, Inc. Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.25 - $2.24 $7,625 - $68,320	30,500 Added 0.36%	8,443,134 $2.49 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $2.51 $976,860 - $1.43 Million	567,942 Added 7.24%	8,412,634 $17.5 Million
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.31 $254,605 - $348,010	150,654 Added 1.96%	7,844,692 $16.3 Million
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $575,308 - $1.04 Million	471,564 Added 6.53%	7,694,038 $14.8 Million
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $4,944 - $6,408	2,400 Added 0.03%	7,222,474 $16.1 Million
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $18 Million - $45 Million	7,220,074 New	7,220,074 $18.4 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.